文献速递消化系统肿瘤

白蛋白紫杉醇联合吉西他滨序贯改良FOLFOX治疗初治转移性胰腺癌的I/II期试验:I期结果

Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results.
PubMed 文献 · Eur J Cancer · 2020-09-22

该I期试验旨在确定白蛋白紫杉醇联合吉西他滨序贯改良FOLFOX方案在初治转移性胰腺导管腺癌患者中的最大耐受剂量(MTD),并评估安全性和疗效。常见毒性包括中性粒细胞减少(73%)、贫血(55%)、血小板减少(55%)和乏力(55%),客观缓解率为50%,疾病控制率为80%。

要点

  • MTD确定为白蛋白紫杉醇125 mg/m2、吉西他滨1000 mg/m2、奥沙利铂85 mg/m2、5-FU推注400 mg/m2和5-FU输注2400 mg/m2。
  • 常见全级别毒性为中性粒细胞减少(73%)、贫血(55%)、血小板减少(55%)和乏力(55%)。
  • 客观缓解率50%,疾病控制率80%,安全性可接受。

核心结论

  • 白蛋白紫杉醇联合吉西他滨序贯改良FOLFOX方案在初治转移性胰腺导管腺癌患者中显示出良好的安全性和耐受性,并具有显著的抗肿瘤活性。

主要发现

  • 所有患者接受最高剂量水平治疗,无需减量;报告1例剂量限制性毒性为上消化道出血。
  • 常见全级别毒性包括中性粒细胞减少(73%)、贫血(55%)、血小板减少(55%)和乏力(55%)。
  • 其他相关毒性包括感觉异常(46%)、恶心(36%)、感觉迟钝(27%)和发热(27%)。
  • 客观缓解率为50%,疾病控制率为80%。

关键数值与推荐

  • 最大耐受剂量(MTD)为白蛋白紫杉醇125 mg/m2、吉西他滨1000 mg/m2、奥沙利铂85 mg/m2、5-FU推注400 mg/m2和5-FU输注2400 mg/m2。

临床怎么用

  • 该序贯方案可作为初治转移性胰腺导管腺癌患者的潜在治疗选择,但需进一步随机II期试验确认疗效并排除长期神经毒性担忧。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although occasioned through different mechanisms, the potential neurotoxicity and also haematological toxicity of nab-paclitaxel and oxaliplatin-based chemotherapy regimen were studied in this trial, which aimed to determine the maximum-tolerated dose (MTD) and to evaluate safety and efficacy of the combination in a sequential regimen of nab-paclitaxel, gemcitabine (GEM) and modified FOLFOX (mFOLFOX) in untreated patients with metastatic pancreatic ductal adenocarcinoma (PDAC). MATERIALS AND METHODS: Treatment consisted of nab-paclitaxel (125/100 mg/m2) plus GEM (1000/800 mg/m2) on days 1, 8 and 15, followed by mFOLFOX (oxaliplatin [85/75/65 mg/m2], 5-FU bolus [400/300/200 mg/m2], 5-FU infusion [2400/2000/1600 mg/m2]) on day 28, of a 42-day cycle. Patients were enrolled at the highest dose level with a subsequent 3 + 3 dose de-escalation plan. RESULTS: Eleven patients (median age = 61, 64% with performance status [PS] = 1) were eligible. All patients received the highest dose level. No de-escalation was needed. A dose-limiting toxicity was reported, an upper gastrointestinal haemorrhage. The MTD was nab-paclitaxel 125 mg/m2, GEM 1000 mg/m2, oxaliplatin 85 mg/m2, 5-FU bolus 400 mg/m2 and 5-FU infusion 2400 mg/m2. Common all-grade toxicities were neutropenia (73%), anaemia (55%), thrombocytopenia (55%) and asthenia (55%). Other relevant toxicities were paraesthesia (46%), nausea (36%), dysesthesia (27%) and pyrexia (27%). Objective response rate was 50% and disease control rate was 80%. CONCLUSIONS: The regimen of nab-paclitaxel plus GEM followed by mFOLFOX showed favourable safety and tolerability profiles with significant anti-tumor activity. More data are being achieved in a randomised phase II trial, to confirm efficacy rates and dismiss long-term neurotoxicity concerns regarding the sequencing of nab-paclitaxel and oxaliplatin.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Carrato A, Vieitez JM, Benavides M, et al. Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results. Eur J Cancer. 2020. PMID: 32977220. doi:10.1016/j.ejca.2020.07.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。